Business Wire

Lexon’s Oblio Named as One of TIME’s 100 Best Inventions Of 2020

26.11.2020 10:57:00 EET | Business Wire | Press release

Share

20 years after making the cover of TIME with their flagship Tykho radio, French design brand Lexon is back on the prestigious publication to reiterate its mission to continuously create disruptive, useful and affordable design objects that improve our daily lives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005899/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Oblio (Photo: Business Wire)

More than just highlighting the groundbreaking French invention, TIME award confirms Oblio’s position as a must-have innovation for today’s world, as it has been crafted in-house primarily as a sleek UV-C sanitizer to prevent the spread of harmful viruses and bacteria that are found on our smartphones, using its built-in UV-C LED technology located on its front interior. UV-C LEDs destroy and eradicate the DNA of microorganisms found in viruses, bacteria, mold, and germs.

Capable of fully sanitizing a single surface at a time, Oblio can deliver a 360° disinfection by simply flipping the phone to expose its second surface for a 20-minute cycle. In terms of effectiveness, Oblio has been proven through lab testing to kill 99.9% of viruses, including H1N1.

Since the beginning of the pandemic, we have seen a growing interest for this product category (UV sanitizer) and therefore, the market becoming rapidly populated with lots of unaesthetic neither truly legitimate solutions. In this context, we're extremely honored and proud to be recognized and awarded for our product's distinct design, its effectiveness and reliability to sanitize our daily essentials and the opportunity to become a must-have solution for today's home and offices.

With the help of media like TIME who are raising awareness around Oblio, with the support and trust of our retail partners who are listing it, we are together making UV-C technology becoming more popular and accessible to everyone, allowing us to collectively participate in a positive change, leveraging innovation to adapt to new behaviors and prevent the spread of virus, which is our common responsibility.” Says Boris Brault, Lexon CEO.

Also acting as a 10W wireless charger, Oblio can fully charge a smartphone in 3 hours and comes with an LED indicator that confirms the correct positioning and charging status of the mobile device.

Appropriately, 'Oblio' is rooted in the Italian meaning for “forgot” the native language of designers’ Manuela Simonelli & Andrea Quaglio. The name hints to the product’s vase shape, thoughtfully crafted to help people disconnect from their screens and enjoy the freedom to be more present for each other, while discreetly sanitizing any mobile phone and fast-charging all Qi-enabled smartphones such as the latest iPhone and Android.

“With such achievements, we’re also proving that France remains an indisputable territory where creativity, innovation and design are prerequisite to sustainable growth, and we hope we can inspire entrepreneurs to believe in their projects and bring them to life.” adds Brault.

Today, Oblio is already available at the most prominent retailers worldwide such as Best Buy, Nordstrom, MoMA Design Store in the US, Fnac Darty in Europe and many more, as well as the official online store: lexon-design.com.

About Lexon:
Since its creation in 1991, Lexon has relentlessly pushed the limits and created a difference in the world of design while remaining true to its commitment to make small objects useful, beautiful, innovative and affordable. Whether in electronics, audio, travel accessories, office or leisure, Lexon has established a special relationship with creativity and partnered with the best designers around the world to create timeless collections of lifestyle products. Following its recent acquisition by BOW Group, a global player in the lifestyle and wearable consumer markets, Lexon is writing a new chapter in its history, experiencing a staggering international growth and digital expansion. Today, with nearly 30 years of existence, more than 200 awards, collaboration with some of the most renowned designers, a retail presence in more than 90 countries across the Globe, Lexon has truly established itself as a worldly-known French design brand.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

International Media contact:
Annabel Corlay a.corlay@lexon-design.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye